Actionable Stock Market Trading Newswire. Built for Traders, by Traders.
All news is property of their respective owners.

Home Newsfeeds Raymond James Maintains Outperform on Ameris, Lowers Price Target to $48

Raymond James Maintains Outperform on Ameris, Lowers Price Target to $48

Raymond James maintains Ameris (NASDAQ:ABCB) with a Outperform and lowers the price target from $50 to $48.

byBenzinga Newsdesk

July 7, 2022

1 minute read

Raymond James maintains Ameris (NASDAQ:ABCB) with a Outperform and lowers the price target from $50 to $48.

No ‘Textbook’ Recession Anytime Soon, Says Stifel Strategist: Here’s What He Said About The S&P 500

By Bhavik Nair

June 7, 8:36 AM

Barry Bannister, the chief equity strategist at Stifel reportedly said there won’t be a textbook recession anytime soon…

QQQ

Apple iPhone Rival Samsung Launches Satellite Connectivity Technology For Its Smartphones

By Anusuya Lahiri

February 23, 12:27 PM

Samsung Electronics Co, Ltd (OTC: SSNLF) secured standardized 5G non-terrestrial networks (NTN) modem technology for direct communication between smartphones and satellites, especially in remote areas.

AAPL

What Does CDW’s Debt Look Like?

By Benzinga Insights

March 17, 1:15 PM

Shares of CDW Inc. (NASDAQ:CDW) rose by 5.45% in the past three months. When understanding a companies price…

CDW

Stephens & Co. Reiterates Overweight on Lifecore Biomedical, Maintains $11 Price Target

By Benzinga Newsdesk

March 17, 8:46 AM

Stephens & Co. analyst Jacob Johnson reiterates Lifecore Biomedical (NASDAQ:LFCR) with a Overweight and maintains $11 price target.

LFCR

Raymond James Maintains Outperform on Ameris, Lowers Price Target to $48

Related Posts

No ‘Textbook’ Recession Anytime Soon, Says Stifel Strategist: Here’s What He Said About The S&P 500

Apple iPhone Rival Samsung Launches Satellite Connectivity Technology For Its Smartphones

What Does CDW’s Debt Look Like?

Stephens & Co. Reiterates Overweight on Lifecore Biomedical, Maintains $11 Price Target